Connect Biopharma Holdings (CNTB) Retained Earnings (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Retained Earnings for 7 consecutive years, with $464.1 million the latest figure, recorded in Q1 2026.

• Quarterly Retained Earnings rose 5.4% year-over-year to $464.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $464.1 million (up 5.4% YoY) and the FY2025 annual result came in at $444.2 million, up 1.1% from the prior year.
• Retained Earnings improved to $464.1 million in Q1 2026 per CNTB's latest filing, from $444.2 million in the prior quarter.
• Over the last five years, Retained Earnings for CNTB reached as high as $464.1 million in Q1 2026 and fell as low as -$531.7 million in Q2 2024.
• A 5-year average of $113.0 million and a median of $439.4 million in 2024 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings fell 20.02% — and 2023, when it soared 196.85%.
• Year by year, Retained Earnings stood at -$446.4 million in 2022, then surged by 196.85% to $432.4 million in 2023, then gained by 1.61% to $439.4 million in 2024, then climbed by 1.1% to $444.2 million in 2025, then climbed by 4.48% to $464.1 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $464.1 million, $444.2 million, and $442.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.